

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

Dated January 26, 2017

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant's Name)

#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272
(Address and telephone number of registrant's principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: January 26, 2017

Aurinia Pharmaceuticals Inc.

By: /s/ Celia Economides

Name: Celia Economides

Title: Head of IR & Communications

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	News Release – AURINIA PHARMACEUTICALS TO PARTICIPATE IN UPCOMING CONFERENCES

Aurinia Pharmaceuticals to Participate in Upcoming Conferences**- Canaccord Genuity Rare Disease Biopharma 1x1 Day on February 7 in New York City****-Leerink Partners 6th Annual Global Healthcare Conference on February 16 in New York City**

VICTORIA, British Columbia--(BUSINESS WIRE)--January 26, 2017--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that Michael Martin, Chief Operating Officer, and Celia Economides, Associate VP of Investor Relations, will participate in the Canaccord Genuity Rare Disease Biopharma 1x1 Day on February 7th in New York City and the Leerink Partners 6th Annual Global Healthcare Conference on February 16th at 11:30am ET. A webcast will be available for the Leerink Conference and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.

About Aurinia

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. The company is headquartered in Victoria, BC and focuses its development efforts globally. www.auriniapharma.com.

We Seek Safe Harbor.**CONTACT:****Aurinia Pharmaceuticals Inc.****Investor & Media Contact:**

Celia Economides

Head of IR & Communications

ceconomides@auriniapharma.com